Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Net Margin: 2013-2025

Historic Net Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to -467.35%.

  • Ocular Therapeutix's Net Margin fell 18489.00% to -467.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -443.25%, marking a year-over-year decrease of 21733.00%. This contributed to the annual value of -259.05% for FY2024, which is 10551.00% down from last year.
  • Ocular Therapeutix's Net Margin amounted to -467.35% in Q3 2025, which was up 6.40% from -499.31% recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Net Margin ranged from a high of -142.09% in Q3 2023 and a low of -589.60% during Q1 2025.
  • In the last 3 years, Ocular Therapeutix's Net Margin had a median value of -247.86% in 2024 and averaged -291.40%.
  • As far as peak fluctuations go, Ocular Therapeutix's Net Margin spiked by 106,001bps in 2021, and later crashed by 37,472bps in 2025.
  • Ocular Therapeutix's Net Margin (Quarterly) stood at -160.25% in 2021, then soared by 1,257bps to -147.67% in 2022, then slumped by 598bps to -153.65% in 2023, then plummeted by 13,326bps to -286.92% in 2024, then plummeted by 18,489bps to -467.35% in 2025.
  • Its Net Margin stands at -467.35% for Q3 2025, versus -499.31% for Q2 2025 and -589.60% for Q1 2025.